About this episode
1) Evidence-based guideline on periprocedural management of antithrombotic medications and neurovascular disease and 2) Topic of the month: Treatment of movement disorders. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Melissa Armstrong about the guideline on periprocedural management of antithrombotic medications and neurovascular disease. Dr. Roy Strowd is reading our e-Pearl of the week about HINTS of stroke. In the next part of the podcast Dr. Binit Shah interviews Dr. Kapil Sethi about management of of non-dopa responsive axial motor symptoms. The participants had nothing to disclose except Drs. Armstrong, Strowd and Sethi.Dr. Armstrong serves on Neurology, Level of Evidence Review Team; received funding for a trip to the MDS International Congress; received research support from Abbott and was partially funded by a Edmond J. Safra Fellowship at Toronto Western Hospital.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Sethi serves on the scientific advisory board for International Essential Tremor Foundation; serves as an editorial board member of Neurology, Journal of Neuroscience, Medscape; is a consultant for Biogen Idec, GlaxoSmithKline, Novartis, Ipsen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Allergan, Inc; serves on the speakers' bureau of Biogen Idec, GlaxoSmithKline, Novartis, Ipsen Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Allergan, Inc; received publishing royalties from Marcel Dekker Publisher; holds stock options in Elan Corporation and Pfizer Inc; involved in legal proceedings for welding litigation defense; receives research support from NPF center, Biogen Idec, GlaxoSmithKline, Teva Pharmaceutical Industries, Ltd., Solvay Pharmaceuticals, Inc., Acadia Pharmaceuticals, Inc. and NIH.